Van ECK Associates Corp Has $227,000 Stock Position in Smith & Nephew plc (NYSE:SNN)

Van ECK Associates Corp lifted its stake in Smith & Nephew plc (NYSE:SNN) by 111.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 9,240 shares of the medical equipment provider’s stock after purchasing an additional 4,865 shares during the quarter. Van ECK Associates Corp’s holdings in Smith & Nephew were worth $227,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. River Road Asset Management LLC acquired a new stake in Smith & Nephew during the 3rd quarter worth about $38,588,000. Point72 DIFC Ltd purchased a new stake in shares of Smith & Nephew during the 3rd quarter worth about $7,200,000. State Street Corp raised its stake in shares of Smith & Nephew by 1.3% during the 3rd quarter. State Street Corp now owns 143,846 shares of the medical equipment provider’s stock worth $4,479,000 after purchasing an additional 1,889 shares in the last quarter. Raymond James & Associates raised its stake in shares of Smith & Nephew by 172.1% during the 3rd quarter. Raymond James & Associates now owns 128,854 shares of the medical equipment provider’s stock worth $4,013,000 after purchasing an additional 81,500 shares in the last quarter. Finally, Citigroup Inc. raised its stake in shares of Smith & Nephew by 18.5% during the 3rd quarter. Citigroup Inc. now owns 119,215 shares of the medical equipment provider’s stock worth $3,712,000 after purchasing an additional 18,630 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew Stock Performance

Shares of NYSE SNN opened at $26.13 on Monday. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $25.04 and its two-hundred day moving average is $27.26. The company has a market cap of $11.42 billion, a P/E ratio of 12.09, a P/E/G ratio of 1.26 and a beta of 0.84. Smith & Nephew plc has a 12 month low of $23.65 and a 12 month high of $31.72.

Wall Street Analyst Weigh In

SNN has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. StockNews.com downgraded Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Finally, Berenberg Bank downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.